Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
  
Advanced search 
 
ORIGINAL ARTICLE
Year : 2019  |  Volume : 15  |  Issue : 65  |  Page : 693-697

Estrogenic activity of glycosides from Cistanche deserticola as an estrogen receptors adjuvant in vitro


1 Research Center of Life Sciences and Environmental Sciences, Institute of Materia Medica, Harbin University of Commerce; Engineering Research Center of Natural Anticancer Drugs of Ministry of Education, Harbin University of Commerce, Harbin, Heilongjiang, China
2 Department of Pharmacy, School of Pharmacy, Harbin University of Commerce, Harbin, Heilongjiang, China
3 Research Center of Life Sciences and Environmental Sciences, Institute of Materia Medica, Harbin University of Commerce, Harbin, Heilongjiang, China

Correspondence Address:
Wen-Lan Li
School of Pharmacy, Harbin University of Commerce, Tongda 138, Daoli District, Harbin 150076
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/pm.pm_402_18

Rights and Permissions

Background: Cistanche deserticola, a traditional Chinese herb medicine, has been widely used for thousands of years with the activities of hormone regulation, immunomodulatory, antioxidative, neuroprotective, anti-inflammatory, and estrogen. Glycosides of Cistanches (GCs) were the main bioactivity components of the herb. Objective: The objective of the study is to study estrogenic activity and the mechanism about estrogen receptors (ERs) of GCs. Materials and Methods: Cell proliferation was measured using the 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyltetrazolium bromide assay for MCF-7 cells. The cell cycle was detected using flow cytometry, and proliferation index was calculated. The mRNA and protein expressions of ERα and ERβ were detected by reverse transcription-polymerase chain reaction (RT-PCR) and western blot analysis as the reported method with minor modifications. Results: GCs group at the concentrations of 1.75, 17.5, and 175 μg/mg could enhance proliferation of the MCF-7 cell lines with a time and dosage-dependent manner. Combined medication group (fulvestrant with estradiol [E2] or GCs) could lead to the incline of proliferation rate compared with the individual medication group (P < 0.01). Flow cytometry analysis indicated that GCs could advance MCF-7 cell lines from G0/G1 phase cells to S and G2/M phase, which could promote cell DNA synthesis. The mechanism of GCs on MCF-7 was similar to that of E2. RT-PCR and western blot analysis indicated that after treatment with GCs for 48 h, contents of ERα and ERβ mRNA and proteins in MCF-7 increased as a dosage-dependent manner with that of GCs. GCs can play a role of estrogenic activity according upregulated mRNA and proteins of ERα and ERβ. Conclusion: This study indicated the estrogenic activity of GCs, and also, ER is the target of GCs. GCs can play a role of estrogenic activity according upregulated mRNA and proteins of ERα and ERβ.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed177    
    Printed7    
    Emailed0    
    PDF Downloaded1    
    Comments [Add]    

Recommend this journal